bioAffinity Technologies Inc. Warrant
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell… Read more
bioAffinity Technologies Inc. Warrant (BIAFW) - Net Assets
Latest net assets as of September 2025: $8.90 Million USD
Based on the latest financial reports, bioAffinity Technologies Inc. Warrant (BIAFW) has net assets worth $8.90 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.55 Million) and total liabilities ($2.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.90 Million |
| % of Total Assets | 77.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.81 |
bioAffinity Technologies Inc. Warrant - Net Assets Trend (2019–2024)
This chart illustrates how bioAffinity Technologies Inc. Warrant's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for bioAffinity Technologies Inc. Warrant (2019–2024)
The table below shows the annual net assets of bioAffinity Technologies Inc. Warrant from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.60 Million | -46.41% |
| 2023-12-31 | $4.86 Million | -56.03% |
| 2022-12-31 | $11.04 Million | +169.94% |
| 2021-12-31 | $-15.79 Million | -4.76% |
| 2020-12-31 | $-15.07 Million | -273.50% |
| 2019-12-31 | $-4.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to bioAffinity Technologies Inc. Warrant's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3872610500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $106.59K | 4.10% |
| Other Components | $56.14 Million | 2157.53% |
| Total Equity | $2.60 Million | 100.00% |
bioAffinity Technologies Inc. Warrant Competitors by Market Cap
The table below lists competitors of bioAffinity Technologies Inc. Warrant ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DTE ENERGY - Dusseldorf Stock Exchang
DU:DGY
|
$1.25 Million |
|
DevvStream Corp. Common Stock
NASDAQ:DEVS
|
$1.25 Million |
|
Aquaporin AS
CO:AQP
|
$1.25 Million |
|
Nickelsearch Ltd
AU:NIS
|
$1.25 Million |
|
DAVITA HLTH CARE
MU:TRL
|
$1.25 Million |
|
Mawson Infrastructure Group Inc
NASDAQ:MIGI
|
$1.25 Million |
|
Rex Industry Bhd
KLSE:9946
|
$1.25 Million |
|
Xinda International Corp
PINK:XNDA
|
$1.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in bioAffinity Technologies Inc. Warrant's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,855,255 to 2,602,036, a change of -2,253,219 (-46.4%).
- Net loss of 9,040,000 reduced equity.
- New share issuances of 4,350,885 increased equity.
- Other factors increased equity by 2,435,896.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.04 Million | -347.42% |
| Share Issuances | $4.35 Million | +167.21% |
| Other Changes | $2.44 Million | +93.61% |
| Total Change | $- | -46.41% |
Book Value vs Market Value Analysis
This analysis compares bioAffinity Technologies Inc. Warrant's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-16.41 | $0.31 | x |
| 2020-12-31 | $-61.29 | $0.31 | x |
| 2021-12-31 | $-64.21 | $0.31 | x |
| 2022-12-31 | $73.64 | $0.31 | x |
| 2023-12-31 | $16.65 | $0.31 | x |
| 2024-12-31 | $6.44 | $0.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently bioAffinity Technologies Inc. Warrant utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -347.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -96.56%
- • Asset Turnover: 1.44x
- • Equity Multiplier: 2.50x
- Recent ROE (-347.42%) is below the historical average (-97.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.90 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.76 Million |
| 2021 | 0.00% | -484411.41% | 0.00x | 0.00x | $-4.75 Million |
| 2022 | -73.84% | -169771.25% | 0.00x | 1.10x | $-9.26 Million |
| 2023 | -163.47% | -313.47% | 0.31x | 1.69x | $-8.42 Million |
| 2024 | -347.42% | -96.56% | 1.44x | 2.50x | $-9.30 Million |
Industry Comparison
This section compares bioAffinity Technologies Inc. Warrant's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| bioAffinity Technologies Inc. Warrant (BIAFW) | $8.90 Million | 0.00% | 0.30x | $1.25 Million |
| Abcam plc (ABCZF) | $15.07 Million | 22.73% | 0.21x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $7.09 Million | -104.63% | 5.72x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.71 Million |
| Adamas Trust, Inc. (ADAMG) | $1.41 Billion | -4.40% | 5.53x | $2.07 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $13.74 Million | 0.00% | 2.67x | $9.38 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $51.99 Million | -0.21% | 3.57x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $1.03 Million | -345.23% | 6.23x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $2.41 Billion | -5.83% | 0.11x | $119.23K |
| Alvotech Warrant (ALVOW) | $-412.77 Million | 0.00% | 0.00x | $35.01 Million |